Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Opthea Ltd ADR (OPT)

Opthea Ltd ADR (OPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Opthea To Present at Upcoming Investor Conferences Globe Newswire - Wed May 11, 2022

MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to...

OPT.AX : 0.650 (+5.69%)
OPT : 3.55 (+3.86%)
Opthea Presentation at The Retina World Congress 2022 Globe Newswire - Tue May 10, 2022

MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel...

OPT.AX : 0.650 (+5.69%)
OPT : 3.55 (+3.86%)
Opthea Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) Presented at ARVO 2022 Globe Newswire - Thu May 5, 2022

MELBOURNE, Australia., May 05, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing...

OPT.AX : 0.650 (+5.69%)
OPT : 3.55 (+3.86%)
Opthea Presenting Clinical Data at ARVO 2022 Annual Meeting Globe Newswire - Fri Apr 29, 2022

MELBOURNE, Australia, April 29, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing...

OPT.AX : 0.650 (+5.69%)
OPT : 3.55 (+3.86%)
Opthea strengthens its Board of Directors Globe Newswire - Fri Apr 22, 2022

Elects Mr. Quinton Oswald and Dr. ...

OPT.AX : 0.650 (+5.69%)
OPT : 3.55 (+3.86%)
Opthea To Present at Oppenheimer’s 32nd Annual Healthcare Conference Globe Newswire - Thu Mar 10, 2022

MELBOURNE, Australia, March 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies...

OPT.AX : 0.650 (+5.69%)
OPT : 3.55 (+3.86%)
Opthea Expands Leadership Team with the Appointment of Joel Naor, M.D., M.Sc., MBA as Chief Medical Officer Globe Newswire - Wed Mar 2, 2022

Key appointment as Opthea progresses the Phase 3 clinical development of OPT-302 in wet AMD MELBOURNE, Australia, March 02, 2022 (GLOBE NEWSWIRE) --...

OPT.AX : 0.650 (+5.69%)
OPT : 3.55 (+3.86%)
Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022 Globe Newswire - Mon Feb 14, 2022

Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical...

OPT.AX : 0.650 (+5.69%)
OPT : 3.55 (+3.86%)
Opthea To Present at SVB Leerink Global Healthcare Conference Globe Newswire - Thu Feb 10, 2022

MELBOURNE, Australia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel...

OPT.AX : 0.650 (+5.69%)
OPT : 3.55 (+3.86%)
Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference Globe Newswire - Wed Feb 9, 2022

MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel...

OPT.AX : 0.650 (+5.69%)
OPT : 3.55 (+3.86%)

Barchart Exclusives

1 Under-the-Radar AI Stock to Grab Now Barchart - 12 minutes ago
This cybersecurity firm is growing rapidly, but has gone relatively unnoticed by Wall Street. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot